NEW YORK and LONDON, Oct. 24, 2013 (GLOBE NEWSWIRE) -- Celsus Therapeutics (OTCQB:CLSXY), an emerging growth, development-stage biopharmaceutical company, announces the appointment of Pablo Jimenez, M.D., to the position of Chief Medical Officer. This appointment reflects Celsus' continued growth as the company advances the development of its lead clinical asset, MRX-6, a non-steroidal anti-inflammatory cream for the treatment of eczema and other skin inflammatory disorders.